Back

PSEN1 mutant marmoset fibroblasts mimic multi-omic signatures of Alzheimer's disease

Kumar, S.; Haber, A.; Spruce, C.; Duong, D.; Seyfried, N.; Bailey, L.; Choi, S.-H.; Hachem, S.; Mou, Y.; Ha, S.-K.; Park, J. E.; Homanics, G. E.; Sukoff Rizzo, S. J.; Silva, A. C.; Carter, G. W.

2026-04-28 genomics
10.64898/2026.04.24.720222 bioRxiv
Show abstract

INTRODUCTIONThe slow, age-related development of Alzheimers disease (AD) and inaccessibility of early-stage brain tissue necessitates model studies to understand its origins and progression. Non-human primate models can provide a platform for linking molecular changes to translatable phenotypes. Here, we assess fibroblast lines derived from marmosets with engineered variants in the PSEN1 gene. METHODSFibroblast cultures were obtained from 10 animals and assayed using a NanoString AD gene expression panel and label-free proteomics. We compared mutant expression changes to human AD signatures in human iPSC-derived neurons and postmortem brains to assess disease relevance. RESULTSGene products involved in amyloid-beta interaction and regulation were differentially expressed, providing evidence for the functional relevance of the engineered fibroblasts. Both gene and protein expression changes in the undifferentiated fibroblasts correlated with human iPSCs from AD donors reprogrammed into neuronal lineages, as well as postmortem brains derived from case-control cohorts. Altered expression profiles were noted based on marmoset donor sex and mutation status, highlighting underlying sex-specific biology relevant to Alzheimers disease. DISCUSSIONThese findings demonstrate that disease-relevant pathways and processes are altered in fibroblasts from mutant marmosets, emphasize the complementarity of transcriptomic and proteomic profiling in AD, and provide a roadmap for more advanced molecular studies of AD in aging marmosets and marmoset-derived cell models.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Alzheimer's & Dementia
143 papers in training set
Top 0.3%
23.7%
2
Neurobiology of Disease
134 papers in training set
Top 0.5%
9.6%
3
Alzheimer's Research & Therapy
52 papers in training set
Top 0.1%
8.6%
4
Molecular Neurodegeneration
49 papers in training set
Top 0.1%
6.7%
5
Acta Biomaterialia
85 papers in training set
Top 0.3%
3.2%
50% of probability mass above
6
Cell Reports
1338 papers in training set
Top 19%
2.5%
7
Scientific Reports
3102 papers in training set
Top 46%
2.5%
8
Nature Aging
51 papers in training set
Top 0.7%
2.2%
9
Translational Psychiatry
219 papers in training set
Top 2%
2.2%
10
Journal of Alzheimer’s Disease
39 papers in training set
Top 0.5%
1.8%
11
Brain Communications
147 papers in training set
Top 2%
1.7%
12
Aging Cell
144 papers in training set
Top 2%
1.6%
13
PLOS ONE
4510 papers in training set
Top 55%
1.6%
14
FEBS Open Bio
29 papers in training set
Top 0.2%
1.3%
15
Acta Neuropathologica
51 papers in training set
Top 0.8%
1.3%
16
Neurobiology of Aging
95 papers in training set
Top 2%
1.3%
17
iScience
1063 papers in training set
Top 20%
1.3%
18
Genome Medicine
154 papers in training set
Top 6%
1.0%
19
Communications Biology
886 papers in training set
Top 17%
0.9%
20
Nature Communications
4913 papers in training set
Top 59%
0.9%
21
The Journal of Prevention of Alzheimer's Disease
10 papers in training set
Top 0.3%
0.9%
22
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
0.9%
23
GeroScience
97 papers in training set
Top 1%
0.8%
24
Science Translational Medicine
111 papers in training set
Top 5%
0.8%
25
Acta Neuropathologica Communications
81 papers in training set
Top 1.0%
0.8%
26
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.8%
27
Frontiers in Neuroscience
223 papers in training set
Top 8%
0.7%
28
Aging
69 papers in training set
Top 3%
0.7%
29
Annals of Neurology
57 papers in training set
Top 3%
0.5%
30
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
38 papers in training set
Top 1%
0.5%